Plain-English translation of NCT07627698 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called EB-DTKN-401, which uses donated immune cells that have been specially engineered in the laboratory to recognize and attack melanoma cancer cells. The treatment is designed for adults with advanced melanoma—either the common skin type or the rarer eye type—that has either spread to other parts of the body or cannot be surgically removed. Researchers want to see if this medication can help shrink tumors and improve survival.
Advanced melanoma is difficult to treat, especially when it has spread or grown beyond what surgery can address. While some patients respond well to existing therapies, many others do not or stop responding over time. This trial exists to explore whether engineered immune cells from donors might offer a new option for patients who have exhausted standard treatments or whose cancers are no longer responding to them.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would first receive medication to temporarily weaken your immune system to prepare your body for the treatment. Then you would receive infusions of the engineered immune cells—up to three doses over about two weeks. The study includes two phases: an initial phase that tests different dose levels to find the safest and most effective dose, followed by an expansion phase where more patients receive the recommended dose. You would have regular visits for blood tests, imaging scans, and health monitoring to see how your body responds.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China